Sep 01, · Neutropenia is a condition in which there are an abnormally low levels of neutrophils (white blood cells) in the blood. Neutropenia can be caused by numerous medical conditions or medications like chemotherapy. Symptoms of neutropenia are skin infections of the skin and other areas of the body, swollen gums, and sore mouth Nov 20, · Gauvreau GM, Boulet LP, Cockcroft DW, et al. Effects of Interleukin Blockade on Allergen-induced Airway Responses in Mild Atopic Asthma. Am J Respir Crit Care Med. Apr (8) [Medline] In one study, plant stanols (up to 9 gm/day, taken throughout the day with meals), helped reduce LDL levels by %. However, a typical range is %. How do plant stanols help lower cholesterol levels? When we digest food, the gallbladder releases bile into the intestines
- Gene ResultIl4 interleukin 4 [ (house mouse)]
Metrics details. Allergic rhinitis AR poses a global health problem and can be challenging to treat. Many of the current symptomatic treatments for AR have been available for decades, yet there has been little improvement in patient quality of life or symptom burden over the years.
In this review, we ask why this might be and explore the pathophysiological gaps that exist within the various AR treatment classes. Eosinophils gm food focus on the benefits and drawbacks of different treatment options and delivery routes for AR treatments and consider how, given what is known about AR pathophysiology and symptomatology, patients may be offered more effective treatment options for rapid, effective, eosinophils gm food, and sustained AR control.
In particular, we consider how a new AR preparation, MP-AzeFlu Dymista ®Meda, Swedencomprising a formulation of an intranasal eosinophils gm food azelastine hydrochlorideeosinophils gm food, an intranasal corticosteroid fluticasone propionateand excipients delivered in a single spray, may offer benefits over and above single and multiple AR therapy options, eosinophils gm food.
We review the evidence in support of this treatment across the spectrum eosinophils gm food AR disease. The concept of AR control is also reviewed within the context of new European Union and Contre les Maladies Chroniques pour un VIeillissement Actif-Allergic Rhinitis and its Impact on Asthma initiatives.
Allergic rhinitis AR is a recognised global health problem. AR eosinophils gm food felt in all areas of daily living, including performance at work and school [ 89 ], and can be associated with poor sleep quality [ 10 ], cognitive and mood impairment [ 11 ], eosinophils gm food, and even the ability to drive [ 12 ]. The burden of AR is also felt socioeconomically, and this, too, is often underestimated and underappreciated [ 45 ].
In fact, others have shown that AR has the greatest negative impact on work productivity of any chronic disease, exceeding that of heart disease and diabetes combined [ 14 ].
The importance of AR control has now been prioritised at the European Union EU level [ 15 ]. AR can be challenging to treat.
Difficult to treat phenotypes have emerged, including mixed rhinitis [both AR and non-AR NAR ] [ 20 ], severe chronic upper airway disease i. uncontrolled disease despite guideline-directed care [ 2122 ], and local AR i. localised nasal allergic response eosinophils gm food the absence of systemic atopy [ 232425 ].
More effective pharmacological treatments are needed to meet these challenges, eosinophils gm food. There are currently many AR treatments available, with antihistamines, leukotriene receptor antagonists LTRAsoral steroids, and intranasal corticosteroids INSs recommended in a step-wise approach according to AR phenotype and severity [ 526 ]. INSs are still considered the most effective pharmacological AR treatment option; newer ones with lower systemic bioavailability have been introduced, but with no differences between them in therapeutic effect [ 2728 ].
One of the most recent additions to eosinophils gm food AR armamentarium is MP-AzeFlu Dymista ®Meda, Swedena novel formulation of an intranasal antihistamine [INAH; azelastine hydrochloride AZE ] and an INS [fluticasone propionate FP ] in a single spray [ 31 ]. Recently published Spanish guidelines also position MP-AzeFlu as a first-line treatment for moderate-severe AR, in preference to an INS for moderate-severe persistent AR [ 33 ], and the update to the ARIA guidelines recommends this combination for seasonal AR SAR [ 4 ].
In terms of current AR management, there are two major gaps. AR patients continue to experience symptoms despite single- eosinophils gm food multiple-therapy AR treatment regimens [ 1734 ]. The aim of this review is to evaluate these gaps and show how recent pharmacological and control-assessment advances help to narrow them.
The pathophysiology of AR is complex, comprising an early- and late-phase allergic response [ 35eosinophils gm food, 36 ]. The early-phase reaction is characterised by mast cell degranulation Fig. This phase is associated with the rapid onset over a period of minutes of acute nasal symptoms i.
sneezing and rhinorrhoea and the emergence of ocular symptoms i. itching, redness, and watering. These symptoms are caused by histamine release, particularly from mast cells in the nasal mucosa. This early-phase histamine release, together with the effects of other potent pro-inflammatory cytokines e.
leukotrienes and eicosanoids e. prostaglandins and kinins also increases vascular permeability, leading to oedema formation. Early and late phases showing the pathophysiological processes and drivers of allergic rhinitis and the potential sites for pharmacological intervention. ECP eosinophil cationic protein, ICAM eosinophils gm food 1 intercellular adhesion molecule-1, IgE immunoglobulin E, IL interleukin.
The late-phase reaction develops over a period of hours after exposure to an allergen. It is characterised by cellular recruitment of basophils, eosinophils gm food, neutrophils, T-lymphocytes, monocytes, and eosinophils, and by the release of multiple mediators, including cytokines, prostaglandins, and leukotrienes, eosinophils gm food, which perpetuate the inflammatory response [ 3536 ].
This late-phase inflammatory reaction is associated with tissue remodelling, further tissue oedema, and the development and perpetuation of nasal congestion, considered by patients to be one of the most troublesome symptoms of AR [ 3738 ]. As a result of mucosal inflammation, tissues become primed and react more vigorously to allergen exposure, eosinophils gm food.
These late-phase reactions and modifications in tissue responsiveness contribute to bronchial hyper-responsiveness Fig. When allergy symptoms are at their worst, on a near-daily basis, patients with AR may feel tired, miserable, and irritable at least some of the time [ 42 ].
The duration and severity of ocular symptoms such as itchy and watery eyes, eyelid oedema, and asthenia have a particularly high impact on QoL, even greater than that of nasal obstruction and pruritus [ 17 ].
Another survey in the United States found that patients with AR were twice as likely to report limitations on eosinophils gm food physical indoor and outdoor activities than those without nasal allergies [ 43 ]. The negative impact on daily activities for patients with AR can be greater than that for patients with type 2 diabetes and hypertension [ 44 ]. Nasal congestion is the hallmark of the allergic response.
This symptom is associated with sleep-disordered breathing, a condition that can have a profound effect on productivity and increased daytime sleepiness [ 45 ]. Furthermore, many of the key pathophysiological mediators of AR responses i. histamine, leukotrienes, cytokines, and prostaglandins play a role in sleep regulation and might be directly involved in this feature of the condition, independent of nasal obstruction [ 47 ]. Pharmacotherapies interact with the AR pathophysiological pathway at different points, reflecting their different modes of action Fig.
LTRAs e. montelukast, zafirlukast, and pranlukast block the activity or secretion of cysteinyl leukotrienes CysLTseosinophils gm food, a potent inflammatory mediator associated with nasal congestion, mucus production, and inflammatory cell recruitment that typifies AR [ 48 ]. Additionally, LTRAs can inhibit reactive oxygen species generation, as well as the release of protease and elastase from isolated human neutrophils [ 5056 ]. However, whether these non-CysLT-mediated effects are physiologically relevant in AR or achievable at clinical drug concentrations remains to be determined.
At concentrations achievable in vivo, eosinophils gm food, oral antihistamines OAHs; e, eosinophils gm food. loratadine, desloratadine, cetirizine, and levocetirizine competitively inhibit the interaction of histamine with H 1 receptors.
At high micromolar concentrations, OAHs may also inhibit histamine-stimulated cytokine release and antagonise or inhibit other mediators of early- and late-phase allergic eosinophils gm food to various degrees [ 5758596061eosinophils gm food, 62 ].
Whether such high concentrations are achievable in the nasal mucosa following oral administration of these drugs is unlikely [ 6364 ]; however, it is likely that the desired concentrations to affect these additional anti-allergic actions are achievable with an INAH [ 65 ]. Intranasal application of antihistamines eosinophils gm food. AZE, olopatadine, and levocabastine ensures delivery of active drug directly to the nasal mucosa, thus enhancing its local anti-allergic and anti-inflammatory effects, while minimising systemic exposure to therapy [ 65 ].
Many studies have shown the efficacy, safety, and tolerability of INAHs for the treatment of AR [ 65 ]; however, the majority of them relate only to AZE. AZE has multimodal action in AR, displaying not only H 1 -antagonist activity but also mast cell-stabilising, anti-leukotriene, eosinophils gm food, and anti-inflammatory effects [ 65 ].
Its antagonism at the H 1 receptor effectively neutralises histamine-induced increases in vascular permeability and capillary fluid leakage responsible for rhinorrhoea, nasal pruritus, and sneezing [ 6667 ].
Mast cell stabilisation occurs as a consequence of AZE, blocking the IgE-regulated calcium channels on mast eosinophils gm food that are involved in mast cell degranulation, thus preventing histamine and other mast cell mediator release e.
tryptase, prostaglandins, kinins, and interleukins [ 6869 ]. Anti-leukotriene effects occur due to prevention of leukotriene release from mast cell degranulation, reduction of leukotriene LT B 4 and LTC 4 production, and inhibition of phospholipase A2 and LTC 4 synthase [ 70 ].
These include eosinophils and neutrophils and mediators such as tumour necrosis factor TNF α [ 71 ], granulocyte macrophage colony-stimulating factor GM-CSFcytokines e. interleukin [IL]-1β, IL-4, and IL-8 [ 7273 ], and adhesion molecules e. intercellular adhesion molecule-1 [ICAM-1] [ 74 ], all of which perpetuate the inflammatory response and induce symptoms of the late-phase response i.
congestion, rhinorrhoea, and hypersensitivity [ 68 ]. Research into the comprehensive pharmacological profile of AZE continues, eosinophils gm food, with a recent study showing that AZE interferes with a specific immune interaction between T cells and dendritic cells in vitro [ 75 ].
INSs are potent inhibitors of the late-phase allergic reaction in AR. They inhibit recruitment of Langerhans cells, macrophages, mast cells, T cells, and eosinophils into the nasal mucosa [ 76777879 ].
This is most likely due to reduction of ICAM-1 expression on nasal epithelial cells, both during the early and late phases after allergen challenge [ 80 ]. INSs may also prevent or reduce airway remodelling via downregulation of nasal fibroblast functions [ 81 ]. INSs potently inhibit inflammatory mediator release from many cells involved in the pathophysiology of AR.
For example, they have been shown to reduce concentrations of IL-4, IL-5, and IL in nasal secretions following allergen challenge [ 82 ], and to suppress release of interferon-γ, IL-2, and IL after allergen challenge in vitro models of human nasal mucosa [ 83 ].
In vitro studies indicate that INSs can reduce IL production in mitogen-stimulated cells [ 84 ] and reduce production of GM-CSF, TNFα, IL-6, and IL-8 generated by cultured nasal epithelial cells [ 85eosinophils gm food, 86 ].
The broad eosinophils gm food actions of INSs may prevent or reduce airway hyper-reactivity in chronic AR, and treatment with an INS has been shown to objectively reduce nasal congestion and nasal histamine hyper-reactivity in children and adolescents with perennial AR PAR [ 87 ]. For eosinophils gm food, at concentrations achieved following clinical dosing, LTRAs are likely to be active predominantly at the leukotriene receptor [ 88 ], whereas OAHs at physiological concentrations will be active predominately at the H 1 receptor [ 6289 ].
Although AZE offers a broad mechanism of action, it does not inhibit mast cell recruitment or interfere with leukotriene receptor interactions [ 65 ]. Likewise, INSs do not inhibit mast cell degranulation or directly interrupt leukotriene and histamine receptor interactions [ 90 ]. As a consequence, no single medication class is capable of providing rapid and complete relief from all symptoms associated with AR Table 1 [ 591 ]. LTRAs and OAHs both act at a single site on the AR pathophysiological pathway and appear to have broadly similar efficacy [ 92 ].
Even so-called new-generation OAHs, such as rupatadine, a dual blocker with anti-H 1 antagonist properties and inhibitory effects on platelet activating factor [ 93 ], may not offer a sufficiently broad-spectrum mechanism of action to affect key pathophysiological drivers of AR. Studies have found efficacy advantages of rupatadine over eosinophils gm food OAHs [ 9495 ], but not over INAHs [ 96 ].
AZE, by virtue of its topical application and multimodal mechanism of action [ 65 ], provides superior congestion and sneezing relief over OAHs [ 97 ]. It also provides superior ocular symptom relief to that of INSs and similar relief from nasal pruritus and sneezing to that of INSs [ 91 ].
However, INSs, eosinophils gm food, as the most potent anti-inflammatory agents, offer superior relief from congestion and rhinorrhoea over AZE [ 91 ]. The areas in which INSs seem to fall short are their inconsistent effects on the eye [ 98 ] and the length of time they take to reach maximal effect.
A range of ophthalmic agents are available for control of AR-associated ocular symptoms; however, their use is limited by poor tolerance for eye drops among many patients, difficulty of administration in a sterile manner, the need for frequent application, and lack of patient compliance [ 99 ].
Thus, patients may need to use INS and OAH for ocular symptom control. Notwithstanding the time course required for efficacy, a number of reviews report that INSs, as a class, have a positive impact on ocular symptoms in AR, improving combined total eye symptom scores, as well as individual symptoms such as redness, itching, eosinophils gm food, tearing, and oedema [, ].
It is speculated that this effect is mediated through the naso-ocular eosinophils gm food however, it should be noted that not all INSs are equally consistent in managing the ocular symptoms of AR, with fluticasone outperforming mometasone in this regard [ 98]. Furthermore, proof of the ocular efficacy of INSs comes from comparison with placebo, eosinophils gm food, rather than with active therapy [, ], eosinophils gm food.
OAHs inhibit some symptoms of pruritus and erythema in laboratory models and have been shown to be superior to placebo in ocular symptom relief in clinical trials. In general, OAHs are considered superior to INSs in relief of ocular symptoms, but some studies have shown equal efficacy with these agents or even superior efficacy with INSs [ ].
However, OAHs, like INS, do not provide a sufficiently speedy ocular response. A combination of topical application and the multimodal effects of INAHs mean that these agents offer effective and rapid ocular symptom relief.
Should we embrace GM food? - five-minute debate
, time: 5:05Food allergy - Wikipedia
Apr 16, · These include eosinophils and neutrophils and mediators such as tumour necrosis factor (TNF)α, granulocyte macrophage colony-stimulating factor (GM-CSF), cytokines (e.g. interleukin [IL]-1β, IL-4, and IL-8) [72, 73], and adhesion molecules (e.g. intercellular adhesion molecule-1 [ICAM-1]), all of which perpetuate the inflammatory response Sep 07, · Gene ID: , updated on 7-Sep Summary Other designations. interleukin-4, B-cell IgG differentiation factor, B-cell growth factor 1, B-cell stimulatory factor 1, IGG1 induction factor, lymphocyte stimulatory factor 1. GeneRIFs: Gene References Into Functions. IL-4 absence triggers distinct pathways in apical periodontitis development A food allergy is an abnormal immune response to food. The symptoms of the allergic reaction may range from mild to severe. They may include itchiness, swelling of the tongue, vomiting, diarrhea, hives, trouble breathing, or low blood pressure. This typically occurs within minutes to several hours of exposure. When the symptoms are severe, it is known as anaphylaxis
No comments:
Post a Comment